Evidence map›Paper›PMID 37406763›Full record

ArticleMetabolic engineering2023

Towards universal synthetic heterotrophy using a metabolic coordinator.

Sean F Sullivan, Anuj Shetty, Tharun Bharadwaj, Naveen Krishna, Vikas D Trivedi, Venkatesh Endalur Gopinarayanan, Todd C Chappell, Daniel M Sellers, R Pravin Kumar, Nikhil U Nair

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolic engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sean F SullivanDepartment of Chemical & Biological Engineering, Tufts University, Medford, MA, 02155, USA.
Anuj ShettyKcat Enzymatic Private Limited, Bengaluru, Karnataka, 560005, India.
Tharun BharadwajKcat Enzymatic Private Limited, Bengaluru, Karnataka, 560005, India.
Naveen KrishnaKcat Enzymatic Private Limited, Bengaluru, Karnataka, 560005, India.
Vikas D TrivediDepartment of Chemical & Biological Engineering, Tufts University, Medford, MA, 02155, USA; Department of Structural Biology and Center for Data Driven Discovery, St. Jude Children's Research Hospital, Memphis, TN, USA.
Venkatesh Endalur GopinarayananDepartment of Chemical & Biological Engineering, Tufts University, Medford, MA, 02155, USA.
Todd C ChappellDepartment of Chemical & Biological Engineering, Tufts University, Medford, MA, 02155, USA.
Daniel M SellersDepartment of Chemical & Biological Engineering, Tufts University, Medford, MA, 02155, USA.
R Pravin KumarKcat Enzymatic Private Limited, Bengaluru, Karnataka, 560005, India.
Nikhil U NairDepartment of Chemical & Biological Engineering, Tufts University, Medford, MA, 02155, USA. Electronic address: nikhil.nair@tufts.edu.

Funding

Metabolic engineering in humans: Altered gut microbes as a therapeutic platformDP2HD091798 · NICHD · TUFTS UNIVERSITY MEDFORD · PI NAIR, NIKHIL UNNI · 2016 to 2016
$2.3M
Developing Synthetic Enzymes to Treat Inborn Errors of MetabolismR21HD105934 · NICHD · TUFTS UNIVERSITY MEDFORD · PI NAIR, NIKHIL UNNI · 2022 to 2023
$344k
NICHD NIH HHS DP2 HD091798NICHD NIH HHS R21 HD105934
6 · The paper itself

Abstract

Engineering the utilization of non-native substrates, or synthetic heterotrophy, in proven industrial microbes such as Saccharomyces cerevisiae represents an opportunity to valorize plentiful and renewable sources of carbon and energy as inputs to bioprocesses. We previously demonstrated that activation of the galactose (GAL) regulon, a regulatory structure used by this yeast to coordinate substrate utilization with biomass formation during growth on galactose, during growth on the non-native substrate xylose results in a vastly altered gene expression profile and faster growth compared with constitutive overexpression of the same heterologous catabolic pathway. However, this effort involved the creation of a xylose-inducible variant of Gal3p (Gal3p

Indexed as

Saccharomyces cerevisiae ProteinsTranscription FactorsGalactoseHeterotrophic ProcessesSaccharomyces cerevisiaeXyloseGalactoseSaccharomyces cerevisiae ProteinsTranscription FactorsXyloseGene regulationMetabolic engineeringMolecular dynamicsSubstrate utilizationSustainabilitySynthetic biology

Identifiers

PMID37406763
PMCPMC10529783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.